DaVita Inc. (DVA) Earnings Call Transcript & Summary
February 10, 2020
Earnings Call Speaker Segments
Jim Gustafson
executiveThanks for joining us for the conference call covering our fourth quarter, and welcome. We're glad you continue to take an interest in our company. Speaking is Jim Gustafson, Vice President of Investor Relations; joining me are Javier Rodriguez, our CEO; Joel Ackerman, our CFO; LeAnne Zumwalt, Group Vice President; and Jim Hilger, our Chief Accounting Officer. Be aware that we might deliver forward-looking statements on this call as defined under the federal securities laws. Known and unknown risks and uncertainties apply to every one of these statements, and those factors could make actual results diverge materially from what the forward-looking statements describe. For more information about such risks and uncertainties, please see the press release on our fourth quarter earnings along with our SEC filing, which includes our latest annual report on Form 10-K and the quarterly reports on Form 10-Q filed afterward. Information currently available to us forms the basis for our forward-looking statements, and we neither intend nor assume any duty to update them. We also want to remind you that certain non-GAAP financial measures will be discussed on this call. You can find a reconciliation of those non-GAAP measures against the most comparable GAAP financial measures in our earnings press release submitted to the SEC and posted on our website. Javier Rodriguez will take over the call now.
Javier Rodriguez
executiveThanks, Jim, and hello everybody this afternoon; we’re grateful for the interest you’ve shown in DaVita and we’re eager to take your questions and comments. I’ll begin with clinical highlights, which serve as a reminder of the life-sustaining care delivered to over 235,000 individuals. Even as we talk about clinical outcomes and bringing down the total cost of care, what we’re aiming for is a better quality of life for our patients. One concrete illustration is our emphasis on cutting down infections among the people we treat. Those under DaVita’s care are susceptible to infection, which frequently results in extended hospital stays and a rise in mortality. I’m pleased to share that their work has produced results. During 2019, we lowered the bloodstream infection rate by 13% and boosted the peritonitis rate by 20% compared with the year before. That’s a significant gain that kept a large number of our patients from being admitted to the hospital. Let me now shift to our results and our outlook for 2020. Our performance in 2019 was strong. We hit the earnings per share and free cash flow growth target that we had set for that year. We’re dedicated to delivering on our 2020 financial guidance, and as a matter of fact, we’re increasing our earnings-per-share target range by $0.50. Joe will walk through the financial specifics for the quarter as well as our 2020 guidance. Let me now take a few minutes to offer our high-level perspectives on clinical matters and on policy; this is an exciting period for kidney care; we’re bridging the transition of care from the nephrologist’s office toward various other types of care. Together with our payers, we’re applying predictive analytics to spot CKD patients facing the greatest risk of transitioning to ESRD. After we support those patients, we’ll concentrate on preventing or postponing the onset of kidney failure; we continue to be enthusiastic about nephrology care lines, the new physician-led entity with close to 1,100 nephrologists that will serve as the vehicle linking DaVita to the nephrologists practice. The aim is straightforward. Deliver world-class analytics and education that help physicians best deploy their time to care for the right person at the right time. And for those patients who do transition to ESRD, we offer both a leading education platform to empower patients to choose to start on the right treatment modality or for them. For patients who chose home modality, we keep investing in our leading home platform, where we serve the most home patients of any provider. In 2019, we saw our high — our highest growth ever in PD modality. We’re working to maintain our leadership in the home dialysis with a 2020 goal of achieving double-digit growth in the PD modality. Turning to policy. We continue our multi-year journey towards integrated care. The quality improvement that’s evident in our demonstration such as the ESCO encourages us. We’re hopeful that additional models and opportunities will emerge to scale integrated care for ESRD patients at national levels. We remain optimistic about the administration's view for value-based care models. The things we've developed, we think, can help everyone reach a shared objective: better clinical results, all while keeping overall spending in check. Lately, there's been plenty of talk regarding Medicare Advantage and the 21st Century Cures Act. Let's keep in mind that when Congress approved that law, the aim was to give Medicare-eligible individuals, including those with ESRD, more insurance choices; as far as how many will actually take them up, nobody truly knows which way patients will go. Our view stays the same — uptake into MA will happen at a slower pace; we're excited to collaborate with our plan partners on overseeing both the treatment and the expenses for these individuals; at the same time, our lobbying work centers on making sure there's sufficient money in Medicare fee-for-service as well as MA. And, as we've noted previously, we're still prepared and keen to push forward with integrated care for the Medicare fee-for-service group. Turning to policies at the state level. We'll continue fighting for our patients in California and elsewhere, where certain labor unions are backing measures that harm patients, drive up costs, and hurt the care delivery system; at this point I'll hand things over to Joe, who can give you more specifics about the quarter along with details on our 2020 guidance.
Joel Ackerman
executiveThanks, Javier. I want to note before we get started that the opening section of this quarter's press release has been changed. Our hope is that this new layout makes it simpler for investors to find several of the key results that in the past showed up farther down in the release; so I'll cover Q4 results first, then turn to 2020 guidance; during the quarter our revenue came to $2.9 billion, which is 2.75% higher than Q4 2018. Operating income reached $463 million, and that figure included roughly $67 million of profit tied to calcimimetics, giving us an operating margin of 16%. Earnings per share from continuing operations came in at $1.86. Let me now walk through a few of the underlying drivers, beginning with what makes up the U.S. dialysis and lab segment. Non-acquired growth during the quarter was 2.1%, which is fairly level with the two preceding quarters. Revenue per treatment fell by $1.10 compared with the prior quarter, and that decline includes a $1.68 per treatment drop in revenue tied to calcimimetics. If you set calcimimetics aside, RPT rose by $0.58%. To sum up how the full-year 2019 went against guidance, once calcimimetics is excluded, we landed at the top of our RPT guidance range of 0% to 1%. On commercial mix, we sold outside the quite narrow range we had given, and 2019 closed with a decline of about 20 basis points versus the prior year. That said, this drop had no meaningful effect on our revenue per treatment. Looking at combined patient care costs along with the dialysis and lab segment, G&A expense declined by roughly $2 per treatment from one quarter to the next, mainly because compensation and benefits costs were lower. Moving to calcimimetics. In Q4 we produced operating income of about $67 million, with revenue per treatment of $12.86 and cost per treatment of $4.19. Across the full year, we produced roughly $220 million in operating income, since we negotiated sizable cost reductions on oral calcimimetics. For 2020, we now anticipate about $40 million to $70 million of operating income from calcimimetics, with around half of that arriving in the first quarter, as we expect ASP reimbursement to fall in later quarters. That said, substantial uncertainty remains around this outlook because the ASP methodology is so complex; let me shift to international; during the quarter, operating income was about $2 million, and that includes an FX loss of $4 million; across the full year, we produced positive adjusted operating income of $2 million, once goodwill impairments are excluded and an FX loss of $2 million is included. Our effective tax rate on adjusted income attributable to DaVita from continuing operations was 25.2% for the quarter and 27.5% for the full year. Both the fourth quarter and full-year effective tax rates got a boost from a reduction in our estimated state tax rate. Now let's discuss cash flow. Operating cash flow from continuing operations for full-year 2019 was $2 billion, and free cash flow came to $1.1 billion. Our cash generation metrics, both operating and free cash flow, got a lift from two things: meaningful gains in our DSOs along with remarkably low cash taxes during 2019. Together, those items boosted cash flow across the year by roughly $300 million. We aren't anticipating a repeat of either one in 2020. Capital expenditures came in at $728 million for the year, a bit under the updated guidance range of $740 million to $780 million, and far beneath the original range we gave at the start of the year of $800 million to $840 million. The stronger Q4 outcome stemmed from the scheduling of certain projects that got moved into 2020. Starting October 1, 2019, we've bought close to 8.7 million shares, paying an average of $64.80 apiece. Thanks to those recent buybacks, our share count has come down by about 41.3 million shares, which is 24.8%, since the DMG transaction closed in June 2019. This week, we anticipate finishing the repricing of our $2.7 billion term loan B, which will cut the interest rate on that debt tranche by 50 basis points. We now anticipate debt expense of roughly $90 million in Q1 2020, followed by about $85 million per quarter in the quarters after that. I'll wrap up with a few remarks about our 2020 guidance ranges; we are raising our 2020 adjusted earnings per share guidance by $0.50 per share, to $5.75 to $6.25. As a reminder, this factors in the anticipated benefits from calcimimetics along with the anticipated cost of the ballot initiative in California. Given the calcimimetics timing I referenced and the expected timing of ballot related costs in the back half of the year, we anticipate some quarter-to-quarter swings in earnings per share this year. Our revenue guidance for the year is $11.5 billion to $11.7 billion, and our operating income margin guidance aligns with the target range of 13% to 14% that we discussed at our Capital Markets Day; we expect to produce roughly $600 million to $800 million of free cash flow this year. I'll note that cash flow naturally swings more than operating income does, because of the timing of working capital and other items like the payroll cycle, tax payments and inter-period shifts in AR collections; that went our way in 2019 and could reverse direction at some point down the road. Operator, let's now open the line for questions.
Justin Lake
analystThanks. Good afternoon. I wanted to walk through a few of the moving pieces here. First, regarding the increased EPS range compared to last year. Would it be reasonable to view roughly two-thirds of that as stemming from the calcimimetics benefit that hadn't been included in prior figures. Perhaps the remainder is due to reduced debt expenses, or maybe you could walk us through any sort of component — other components such as California sort of pushing back the rollout of the legislation there regarding the ACAS?
Joel Ackerman
executiveSure; so, Justin, you've got the fundamentals right. Calcimimetics represents the largest piece of this. And a reduction in the — in the cost we anticipate for AB 290 factors into this too. Those are the two major items I'd highlight. There are numerous other moving parts in here. Our share count fluctuates as the stock price rises along with a whole bunch of other things tied to core OI. But I would say, calcimimetics in the AB 290 are the two major items to highlight.
Justin Lake
analystGreat. Perhaps you could give us an update on whether anything has changed regarding how sustainable calcimimetics are in your view past 2020, or do you continue to anticipate that it will drift down to roughly neutral? And then, is there a fresh AB 290 figure you can share? I believe the prior one was 25 to 40.
Joel Ackerman
executiveSure. Regarding calcimimetics, we continue to anticipate that under the existing TDAPA it will drift down to zero across 2020. We have been — we — as you can see, predicting how ASP would decline has not been possible for us. The positive figures for 2020 stem from ASP not declining the way we thought it would three months back. Whether our visibility into how the rest of the industry has acted, combined with certain black box aspects of ASP, has gotten better, I'm not sure, but we do believe this needs to get quite near zero by year-end. On AB 290, no new figure is available from us. Obviously the figure will be lower; nonetheless, some legal costs tied to AB 290 will exist, and there is definitely a chance it gets implemented near the end of the year; so the figures are reaching a size where calling out a specific figure isn't worthwhile in my view, but clearly under the 25 to 40.
Justin Lake
analystAll right. One final quick question before I return to the line. On the calcimimetics, would it be reasonable to state that in your view expenses have declined to something like a typical level, and all we have to do is monitor the ASP so that it drops <<inaudible>> toward roughly that $4 figure?
Joel Ackerman
executiveCorrect, I'm not claiming cost couldn't keep sliding downward somewhat, but what truly matters for 2020 concerns where ASP is headed.
Justin Lake
analystThat's useful, thank you.
Kevin Fischbeck
analystI'd like to dig into the current year's outlook relative to what you told us for 2022, since across many of your measures it seems you've roughly arrived at the midpoint of that 2% yearly revenue growth target. So I'm trying to get a handle on that starting point. Does it remain the correct baseline, or has something emerged here that suggests we should view the longer-term path differently? When we look at how this year's guidance compares with the '22 figure, my understanding is that '22 will face a drag from calcimimetics going away. On top of that, your guidance continues to bake in AB90 taking effect. I just want to confirm that this is one item we need to sort out as we work through this?
Joel Ackerman
executiveYeah, you've nailed it on both counts — calcimimetics exiting this business and AB 290 taking effect. As for the other items I mentioned, regarding the cash flow figure, 2019 came in remarkably strong, and in the script we highlighted two contributors: a reduction in DSOs and cash taxes. I should add that calcimimetics also gave cash flow a boost, along with the effect that had on OI. So that materialized more quickly than we'd anticipated. On top of that, we got some lift during the year because certain CapEx we'd projected for late in the year slipped into 2020. That could end up hurting the 2020 figure. It's definitely possible that when 2020 wraps up, some of it slips over into 2021, and that might go in either direction. One more item worth mentioning is margins. We discussed a range of 13% to 14%. Our outlook there hasn't shifted at all, so when you're estimating what margins might look like in 2022, that's the figure I'd keep using.
Kevin Fischbeck
analystAll right, that's useful, and I do appreciate the early remarks regarding MA. However, my sense is that a number of the managed care organizations are beginning to be concerned that this will become a problem for them as we move into 2021. So could you discuss the discussions you are currently having with your MA partners? Are rates being resisted, or is there anything else you would point to that might alter or affect how this lands on you across the coming years?
Javier Rodriguez
executiveThank you, Kevin; Javier here. We have received quite a few inquiries about MA, so I believe it helps to step back a bit and go over where this came from. First, this is the sole patient group, the ESRD population, that had been left out of the ability to choose MA. So it corrected a gap in the system. Second, what will our part be moving forward? Our part is simply to ensure our patients are properly informed so that each can make the choice that suits them best. Third, everyone is attempting to estimate it, and when you attempt to estimate something of this kind, there are 2 factors, naturally: one being rate, the other being volume. So what we have stated is that our rate sits above Medicare yet well beneath commercial. We will not concede anything further on that factor. The one that remains most unresolved right now is how much volume will come in, and all of you are aware, just as we are, that numerous factors are in play when an individual has primary insurance, secondary insurance, whether they hold Medigap coverage and so forth. Thus we keep believing it is sensible to expect that penetration will mirror the broader market. Furthermore, plenty of people assume our patients will have something like a hair-trigger tendency to select an insurance plan when the variables are so complex, and since many of them have been in Medicare for a long while, the status quo may simply persist. So we are essentially asking how our patients will read their benefit, and therefore we do not know, and plenty of people keep estimating that it will be some form of forceful shift, while we keep believing it will be more of a gradual one.
Kevin Fischbeck
analystThat's certainly useful. Two things come to mind about this. Regarding the rate gap you have right now, is there any factor that leads you to believe it couldn't be maintained, for whatever reason? By any normal metric, you'd obviously just want to narrow that difference eventually, but is there anything that makes you think that might happen — or perhaps you could retain those economics, which might alter how you actually negotiate with managed care, assume more risk, that sort of thing?
Joel Ackerman
executiveYeah. I'd view it as a chance for us to broaden how we engage with our contracts and with our payer providers. It's an exciting moment when everyone is aligned on making sure patients receive integrated care, so we're stepping up and exploring how we can serve them best and act as a partner. And if their expectation for MA volume exceeds ours, that could be another chance to structure a contract that way. So we're enthusiastic. Naturally, they're after lower rates; we'd prefer higher ones, and that tug-of-war will always exist; the real question is whether we can all find creative ways to reach a win-win outcome.
Kevin Fischbeck
analystAlright. Then regarding what you said about movement toward MA — I take your point that folks often stick with what they know for health coverage, since changing feels pretty intimidating — but my assumption is that the ability to sit down with these individuals on three occasions and walk through the choices could shift that pattern, and in the 20 states where MedSup isn't offered to those under 65 at a price they can manage, I'd expect take-up to be fairly substantial. What I'm really asking is this: in states where MedSup is offered, does any logic exist for those patients to leave a MedSup plan for an MA plan? And likewise for dual eligible groups, who make up 40% of your Medicare book — is there a reason for those patients to make a move? And why would either group perceive an advantage in an MA plan?
Javier Rodriguez
executiveYes, that first idea you raised — being able to reach the patient — deserves some examination, since you may be better at this than we are: when you bring up insurance with someone, it isn't typically like Netflix or something similar. Nobody's eager to keep watching the next episode. Usually folks start to zone out a little, and once you mention deductibles, once you mention coinsurance, once you mention things along those lines, that vocabulary isn't what most of these people use day to day. Plus they've had Medicare for a while and it's working for them. So then you have to begin explaining that perhaps it's more limiting, perhaps their doctor isn't in network, yet it comes with other advantages, and as you get into it you notice some people simply stop listening; so the real question becomes whether it's our duty to approach them again. I'd say the answer is no, since you're happy with your coverage. Our job is just to ensure a fresh choice exists for you. And with all these — with the duals, sometimes out of pocket costs could be extremely small, so switching may not appeal in that case; so it really depends on each person specifically, but once more, the bottom line is we don't expect to appear much different from the broader population, though there's a range all of us are working within.
Kevin Fischbeck
analystAnd then just one final thing. Is there a window when you think you'll have a sense of how that transition is progressing? Will that become clear over the course of open enrollment in Q4, or is it really necessary to hold off until January before patient claims begin arriving under the new payers?
Javier Rodriguez
executiveWell, my sense is that we'll need to hold off until January; we'll get a bit of early information, but it's unlikely we'll want to forecast how that will unfold before we actually observe it, given that this marks our first time going through it.
Kevin Fischbeck
analystRight. Great. Thank you.
Javier Rodriguez
executiveThank you, Kevin.
Pito Chickering
analystHey, everyone. I appreciate you letting me ask a few things. There are several items I want to cover. Regarding the 2020 revenue guidance, what assumptions are you making about organic treatment growth and revenue per treatment? Also, how does commercial reimbursement appear for 2020?
Javier Rodriguez
executiveAbsolutely. So, hey, regarding NAV, we've — our guidance is 1.5% to 2.5%. When it comes to revenue per treatment, we won't be providing guidance on RPT with the same degree of specificity as before. Having said that, I believe it's reasonable to state that moving forward it will resemble what we saw recently. The same pattern regarding commercial RPT, Medicare RPT, and mix ought to unfold next year as it did across the last two years. The one significant shift, clearly, involves Medicare fee-for-service reimbursement. We received that in '19 and we expect it to persist going forward; so, once more, when we consider how we wish to guide — and this aligns with what we elevated at Capital Markets Day — there's more emphasis on margin rather than any individual inputs; having said that, if you consider the inputs of RPT and its subcomponents along with cost per treatment and the other elements, we don't foresee anything notably different next year worth highlighting compared to what occurred recently.
Pito Chickering
analystGreat. Now regarding the 2020 margin guidance, let me pose it in another manner. If calcimimetics are taken out for 2020, I believe the operating income margin is 12.5%. If we remove $47 million of calcimimetics for 2020, it appears you're steering toward roughly a 50 basis point gain in 2020 compared to 2019? The first quarter of '18 was a quite simple comparison, so if calcimimetics are excluded for 2019 and 2020, and the simple comparison of first quarter '19, how should we consider core operating income margin in 2020 compared to 2019?
Joel Ackerman
executiveOkay. Pito, your math lost me there, but I'll explain how I think about my math and I'm sorry if this doesn't align closely with your question, but you can check with Jim later. So for adjusted normalized figures, so this leaves out calcimimetics, we landed just above 14% in 2019; we anticipate that — and once more, we are not guiding to OI. So we — once more, we stated that calcimimetics — at Capital Markets Day we are maintaining that. That said, either via a top-down analysis using revenue and our margin guidance or bottoms up through EPS, all of you can perform the math and arrive at a range. So, I'm going to offer some high-level thoughts relative to what's probably the middle of the range of what you ought to be considering, which should indicate a little bit of margin compression in 2020 compared to 2019, although still very much within that 13% to 14% range we discussed at Capital Markets Day; and if I must identify what is causing that, you have a little bit of AB 290 in there. There's the ongoing pressure on labor costs tied to the strong environment we are in and we are also considering making some investments in the form of operating costs, investing in our future around areas like home, areas like integrated kidney care, areas like data and analytics. So if you combine those — all those things together, you would arrive at a little bit of margin pressure in 2020 over 2019, but still very much within the range of what we discussed at Capital Markets. Is that helpful?
Pito Chickering
analystYes, absolutely. So this is really kind of the final question. During the Analyst Day, you discussed capital — capital expansion, with CapEx declining to 615 in 2022; and you kind of — you just brought up sort of kidney start home based programs. Could you put a number on how many of your centers currently offer distinct home treatments options, and how many are freestanding home centers too?
Joel Ackerman
executiveThat, I don’t have an answer for.
Javier Rodriguez
executiveWe're going to circle back on that.
Joel Ackerman
executivePito, we can circle back with you on that one.
Pito Chickering
analystGreat. Thanks so much, guys. I appreciate it.
Andrew Mok
analystHi. Good afternoon. I just wanted to follow up regarding the components of the 2020 guidance, considering all the moving pieces. You increased EPS guidance by $0.50; it sounds like that bump is mostly explained by the calcimimetics benefit plus the reversal of AB 290. So would it be fair to say the underlying assumptions about share repurchase stay the same, given the $2.4 billion of buybacks you completed in 2019 along with the nice run-up in the stock price over the last few months? How should we think about the magnitude and timing of share repurchase in 2020?
Javier Rodriguez
executiveSure. Our approach to buying back stock remains rooted in the same principles as before — we concentrate on intrinsic value and guard against paying more than what we judge that value to be. Beyond that, we generally aim to remain within our 3x to 3.5x leverage guidance most of the time, though not always. I want to pause here and point out that the leverage figure shown in the press release comes to roughly 3.1, placing it at the bottom end of that range. When you set calcimimetics aside—and in my view that gives you a clearer picture—the result lands at the top portion of our guidance range. Even so, nothing about how we approach repurchasing shares has shifted. What has shifted, compared with our November conversation, is the share price: it moved from the upper 50s and lower 60s into the 80s. That development shapes our thinking on buybacks in two key respects. First, since the price per share is higher, the same amount of money devoted to repurchases ends up acquiring a smaller number of shares. And then, when we consider what the business is truly worth versus the current share price, that share price is going to play a major role in shaping our approach to repurchasing stock. So we aren't going to provide any preview of our intentions. That's something we've consistently avoided doing. Still, I wanted to offer all of you something of an update regarding our current thinking on this. Quarter Great. I appreciate that context. My second question is about home dialysis. The mandatory model tied to the executive order was expected to take effect a month ago, and it has now been pushed back. Have you picked up anything from Washington about the reasons for that delay? So, when a model gets pushed back—whether that's just for now or forever—does that change how you're trying to grow home penetration? Not at all. Broadly speaking, that executive order covered a great deal, and when they opened it up for feedback, the community came together with a pretty consistent message. We're glad the administration chose not to move too quickly, because our priority is landing on something durable rather than simply meeting a deadline. Now, on your other question, the answer there is also no—at the end of the day, policy does matter, sure, but the decision about which modality to use rests with the patient and the physician, and that's what's really driving the movement toward home. Whether individuals choose it or don't choose it, that's what counts, rather than any policy shifts at this point.
Andrew Mok
analystOkay, great. Thanks.
Javier Rodriguez
executiveThank you.
Stephen Tanal
analystGood afternoon, everyone, and thanks for taking the question. I'd like to revisit that 2021 rule change. What I'm having trouble reconciling is the expectation that ESRD patient penetration ought to match the broader market, given that right now, for the market at large, ESRD patient penetration sits at 25% even though those patients aren't able to enroll in the plan freely. Doesn't that suggest this patient panel likely favors MA, and that penetration might climb past 35% down the road? And I know we're still holding to that anchor, but it seems CMS, with last week's adjustments in the advanced notice for MA rates, raised its forecast to 33 and 21, then moving to 42, 41x22 through 2024, and 42 after that. So clearly a far more optimistic view than yours; any reaction to those points?
Javier Rodriguez
executiveYes. Steve, I'd say every one of those opinions is quite reasonable, and we don't claim to be right. We're all working off the same data when it comes to economic deductibles, out-of-pocket max, and that sort of coordination of care network — narrow networks or broader network. So once we put all the variables in place, we simply think that, generally speaking, it'll take a bit longer for people to settle into the choice than others who believe it will be what I'd call a very efficient and effective market, and of course we could be wrong. So there's that range — let's call it the low, the base case and the high case — and we don't have any additional insight that you or CMS lacks. There's no detail information that we are relying on.
Stephen Tanal
analystThat's useful. All right, and then, Joel, I want to confirm I heard you right when you talked about ensuring patients know what choices they have. My assumption is that this holds true in every state, whether or not MedSup has guaranteed issue. Am I right about that?
Joel Ackerman
executiveThat's right.
Stephen Tanal
analystAll right. Then I suppose I also wanted to inquire about a different portion of that suggested regulation, assuming you folks have enough time to review everything, but the network adequacy proposals—there are several items in there. I won't walk through every one of them right now, though a few could arguably be interpreted as potentially reducing some of the market power and dialysis. What's your take on that dynamic, broadly speaking? I suppose I'd keep it open-ended. I don't want to discourage anyone or share, maybe I guess?
Joel Ackerman
executiveThanks, Steve. Clearly, network adequacy matters greatly in any disease state. Once you're enrolling in a product, you need assurance that it has coverage, so that if you do enroll and later develop ESRD, you don't wind up with some form of restricted network. And naturally, whether it's included or not is significant. The plans have spoken up quite a bit. And from where we sit, what we're aiming to do—returning to what we discussed previously—is we're aiming to shift the dynamics with our payer partners so they recognize what we're doing and how we're contributing value, so they do want to contract with us in a manner that benefits both sides.
Stephen Tanal
analystGreat, that's useful. Perhaps one more thing on this, and then I'll hand it over. Returning to the treatment deltas, the MA fee-for-service. I realize you folks prefer not to provide a specific gap, but could you perhaps speak to how much variation exists within that spread? And which elements determine DaVita's readiness to agree to smaller versus larger spreads across various MA plans?
Javier Rodriguez
executiveWell, Steve, I'm grateful for the question, though I suspect you're aware it stood little chance of getting an answer. At this moment, each plan is determining its approach to contracting with us. And honestly, even were I to attempt a response and try to be useful, every contract is highly particular to that individual plan, to their capacity to bear risk and ours, so it's quite particular; thus, regrettably, I'm unable to offer you additional specifics on that.
Stephen Tanal
analystThat works. Many thanks. I’m grateful.
Joel Ackerman
executiveThanks.
Whit Mayo
analystHi there, thank you. Hope everyone’s having a good afternoon. I’ve got a few questions about calcimimetics. Your guidance for OI this year is $40 million to $70 million. Half of that lands in Q1, which suggests roughly 25% of the current $220 million run rate during the first quarter; so I’m wondering what assumptions sit behind that? Does it reflect the ASP for the quarter as it stands today? At this point, how much line of sight do you actually have into what Q1 will contribute? That’s really my question.
Joel Ackerman
executiveOur visibility there is fairly solid. I believe the ASP figure was released in December. It’s not complete visibility, but — so we have that for Q1. Where we lack complete visibility is how things trend from here, and we won’t have the Q2 ASP for some time yet.
Whit Mayo
analystAlright, so it appears as though ASP is down roughly 60% from the fourth quarter on a sequential basis, correct?
Javier Rodriguez
executiveWhit, we are …
Whit Mayo
analystDo you happen to know …
Joel Ackerman
executiveAdditional elements play a role in that. When it comes to the drop in cost, the shifting blend of Sensipar and Parsabiv along with the difference in Parsabiv's cost; so I doubt a number as clean as what you're hoping for can be pulled from that, but …
Whit Mayo
analystI'm guessing the average selling price figures are out there, so are you able to share what that came to for the quarter?
Joel Ackerman
executiveSure. It declined somewhat beyond 40%.
Whit Mayo
analystAll right. So a different element would be pushing your expenses higher, causing operating income to drop by 60%?
Javier Rodriguez
executiveWell, yes — cost isn't the only thing at play, since there's also a mix dynamic involving both the oral and the IV.
Whit Mayo
analystYeah, yeah, understood. Understood. All right. That is — and considering the rest of the $50 million or — not $50 million, but the earnings that are left, how do you — I mean, are we — what's the right way for us to think about how that earnings will move? Does it decline evenly across the year? I'm not sure, any guidance at all? I mean, I realize you have roughly the same level of visibility on this as we do.
Javier Rodriguez
executiveYeah, if you're looking at it being reduced by half every quarter from here on out, that's a sensible rule of thumb to apply, and then it reaches zero at the close of the year.
Whit Mayo
analystAll right.
Javier Rodriguez
executiveOnce more, I want to be clear that isn't a forecast. It's simply meant to assist everyone here with your modeling.
Whit Mayo
analystSure. Could there be a situation in which, right around when the sector starts to notice that the calcimimetics benefit has gone to nothing, you're still holding onto a certain amount of earnings from calcimimetics, since presumably you've been purchasing under market rates for a while now?
Joel Ackerman
executiveProbably not, simply because the figures become so tiny when it comes to the cost. What I find more intriguing regarding calcimimetics is, in the end, the way it ends up being bundled.
Whit Mayo
analystYes, the bundled approach.
Joel Ackerman
executiveThe TDAPA matter is going to unfold fairly fast.
Whit Mayo
analystAll right. A few more quick items; returning to the NAG guidance of 1.5 to 2.5, that does suggest a certain amount of deceleration. Joe, are there any factors behind your choice to lower that range?
Javier Rodriguez
executiveI'll take that one; Javier here; we keep examining the macro ranges, and we simply believe that's the appropriate spot to settle; we're still putting money into our missions, into our IT, into every other operation to make patient placement simpler. Yet ultimately, our focus is making sure we possess the discipline and capital needed for profitable growth. So we won't pursue volume. That's simply not the correct approach for us. Therefore we're at ease with that range of 1.5 to 2.5.
Whit Mayo
analystAll right, thank you.
Javier Rodriguez
executiveAnd only so you know, if I'm recalling correctly, that's not something different on the capital markets side; ours was at 1.5 to 2.5, though I might be mistaken. So let's verify that.
Gary Taylor
analystHello, and good evening. I have only a few more inquiries remaining. First, returning to what was asked regarding the ETC — that required demonstration which has been pushed back — can you see at all when it might begin? Are there any expenses you're taking on to get ready for it? And I assume that because that model involved certain reductions in dialysis center reimbursement, which you might be able to recover given this postponement, no possible monetary effect has been factored into the 2020 guidance?
Javier Rodriguez
executivePut simply, we possess no additional details beyond what all of you have. Just like every provider, we received a chance to share our views and perspective. That we did, and they are reviewing it, and we've gotten no response. At this moment we aren't bearing any expenses tied to it; and it wasn't included in our guidance; so as things stand you're at parity, Steven, so to speak, nothing has shifted.
Gary Taylor
analystAll right, thank you. For my final question, I'll direct it to Joel. I was hoping you might be able to go over and make clear for us, whether we look at it through EPS or through dollars, exactly what sits in 2020 regarding advocacy expenses, since I'm aware that during the third quarter you raised that figure by $0.50, or roughly $87 million before tax. Yet my understanding is that this came on top of what you consider your usual, recurring advocacy, but afterward, with the AB 290 postponement, perhaps a portion of those expenses flowed back your way. So perhaps you could give us some assistance when we consider the 2020 guidance, on how much beyond what you'd describe as your typical advocacy spending has been incorporated into 2020.
Joel Ackerman
executiveCertainly; nothing has truly shifted on that front, Gary. There has been no interaction whatsoever between what we spend on the 2020 ballot initiative and AB 290. Those two are quite separate. Therefore $0.50 per share is the correct figure, and it sits on top of the $30 million baseline we intend to spend annually. One thing I'd amend in your figures is that these ballot initiative expenses cannot be deducted for tax purposes. As a result, your $87 million pre-tax amount is too high, because I suspect you arrived at that figure by presuming it would be tax deductible.
Gary Taylor
analystRight — I remember hearing from you that the figure was roughly $60 million to $65 million, most likely; so …
Joel Ackerman
executiveOur position remains unchanged at $0.50 per share. So …
Gary Taylor
analystOkay. All right. Thank you.
Justin Lake
analystThanks. Let me just work through one item from the questions I still have left here. First, regarding the money you have on hand that could be put to work. If I remember correctly, you generally aim to keep roughly $500 million at the parent when a quarter closes. So would it be reasonable to assume you have approximately another $500 million, more or less, of usable cash on your side — is that accurate?
Joel Ackerman
executiveYes, that’s essentially correct. $500 million is usually the amount we like to keep in the system. So, yes, the $600 million is the figure above that.
Justin Lake
analystAll right, that's useful. Then, Joe, you've been discussing how intrinsic value is now entering the repurchase picture. Given that you bought back a huge amount at a very appealing price to the advantage of shareholders, and with the stock now in the 80s, it seems like you'll be doing somewhat fewer <<inaudible>> around those levels. Should we infer anything about how you see intrinsic value at today's price? And what you anticipate beyond x-stock? Could you provide something like a current update?
Joel Ackerman
executiveSure; we have — we've never actually been prepared to discuss our opinions on intrinsic value at any given point, and I don't plan to make an exception here. One point I would make is that intrinsic value moves; it doesn't remain fixed, and it's affected by our results, and it can be affected by our repurchases and all sorts of other things. So I think our opinions on intrinsic value from six months back are inevitably the same as our opinions on intrinsic value now.
Javier Rodriguez
executiveThere's a dynamic here, Justin, that people seldom discuss out in the open, which is that we have significant blackout periods. On top of that, you've got a plan in place, plus we face restrictions and that sort of thing. So the way to approach this isn't to focus on a single quarter or a pair of quarters — instead, look at the whole picture of what our track record shows. And I believe when you examine that track record across time, it comes across as pretty fluid, in line with the point Joe made.
Justin Lake
analystThat completely makes sense. Thank you. And then, quickly, regarding your commercial mix. Joe, you mentioned it declined 20 basis points versus the prior year, yet there wasn't really a material effect on revenue per treatment. Could you provide a bit more detail on that, since that metric is so important?
Joel Ackerman
executiveYes. Look, all commercial payers aren't the same, and when the mix shifts toward payers offering lower rates, the effect on our RPT is far smaller than it would be with a payer at an average rate.
Justin Lake
analystSo, rather than this simply reflecting the usual demographic aging pattern, would you say you deliberately chose to step back from certain contracts that carried lower prices, or did it simply happen that way?
Javier Rodriguez
executiveYeah, I'd say what Joe mentioned at the start, in response to an earlier question, remains true — namely, nothing new is at play, and by and large the ecosystems and the negotiation process stay fairly steady. No major choice was made in either direction, and matters will unfold as they will.
Justin Lake
analystAlright. There are a few more items I want to touch on. First, Joe, I just want to confirm something. You aren't providing OI guidance, but going back to what Pito asked about margins, core margins excluding the various moving pieces are slightly lower compared with a year ago, while revenue is slightly higher. So essentially, core OI <<inaudible>> items like that are — within the guidance you've given, it's basically unchanged versus a year ago. Does that seem like a sensible way to look at it?
Joel Ackerman
executiveI don't want to get pulled into the OI guidance discussion, since we aren't giving guidance on OI; that being said, I think once again you can view the range either from the top down or from the bottom up. I'd say it's reasonable to state that at the midpoint of the range, you ought to anticipate a bit of OI growth compared with a year ago.
Justin Lake
analystSo basically, aside from some moving pieces.
Joel Ackerman
executiveAlong with pressure on margins, which I'd describe as unlikely to expand as quickly as the top line.
Joel Ackerman
executiveJustin, you've got it right — that figure represents the core, leaving out calcimimetics along with the other items, basically the other noise.
Justin Lake
analystUnderstood. And perhaps a brief comment — I believe the industry intended to launch its own ballot initiative in California, then chose not to move forward with it. Is there a particular reason you pulled back, or am I mistaken about that?
Javier Rodriguez
executiveNo, you've got that correct. And the best way to frame it, Justin, is that very early on, every possibility has to be examined. There are certain filing restrictions, and so on. So we were looking into that option, making certain we had all resources available to us. Once we assessed it, we concluded that pursuing it wasn't the right call. It doesn't serve our strategy well, and it's tidier to address things directly — quite literally head-on — rather than resorting to a counter measure.
Justin Lake
analystAll right, I appreciate you all taking the time.
Javier Rodriguez
executiveThanks, Justin.
Maggie Jiang
analystI appreciate you letting me ask a question. What I'd like to know is where international growth ranks among your priorities. Looking at 2018, I can see roughly 241 centers outside the U.S. I'm not certain whether that figure rises in 2019.
Joel Ackerman
executiveOf course. Our international priorities mirror those we have domestically — namely, growth achieved with efficient use of capital. We still view it as a business that grows. We keep putting capital to work in those markets we judge to hold the strongest opportunities, and those are chances either to buy assets at appealing prices or to develop de novos at appealing prices, and where we can contribute something extra. So expansion during '19 came in fairly close to what we had anticipated. We expect 2020 to stay on that same course.
Maggie Jiang
analystAll right. Now regarding how the international business will grow over the long term — since each region has its own kind of reimbursement setup, its own affordability levels, and its own customers and clientele — would you anticipate that international profitability differs from what you see in your core U.S. business?
Javier Rodriguez
executiveMy sense is that this will differ quite a lot from one country to the next. As you pointed out, certain countries reimburse better, while others do so to a lesser degree. So I believe there will be somewhat of a blend, and where things end up compared with the U.S. is going to hinge heavily on the varying mix across those countries and on which places we decide to put our investment dollars first. That makes it tough to say right now what the final margin will look like next to the U.S. margin.
Maggie Jiang
analystAll right. And given that overseas accounts for approximately 4.5% of revenue, but if I simply compare Q4 2018 with Q4 2019, the increase in international revenue comes to 6.45%. That looks like a stronger area than overall revenue growth of about 2.7%. So do you expect you'll keep pursuing international, especially China? Yet on the other side, we do observe a loss — net operating loss — from international.
Javier Rodriguez
executiveWell, yes, I believe we will keep investing internationally, regardless of whether it expands more quickly than the U.S.; we aren't providing specific guidance about that. Still, I'd say using the past as a guide to the future seems reasonable there. So, yes.
Maggie Jiang
analystGot it; and then regarding Asia — your presence there, I notice you have some branches and several centers across Taiwan and China. Plus, you're collaborating with the APAC JV as well. Could you give me an idea of what your business model looks like and how you go after China or Greater China?
Javier Rodriguez
executiveWe typically don't provide much granularity about specific countries. So I'll skip answering that one.
Maggie Jiang
analystThank you.
Javier Rodriguez
executiveThank you, Maggie.
Javier Rodriguez
executiveOkay, I appreciate everyone taking the time to join; we're eager to speak with you once more. And we'll put in our maximum effort to fulfill everything we've pledged. Thanks, and let's connect again before long.
Operator
operatorAnd that concludes today’s conference. Thank you for your participation. You may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete DaVita Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to DaVita Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in DaVita Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.